Response rates of approximately 40% for significant regrowth mean most users experience maintenance or modest improvement rather than dramatic restoration
Interest in the drugs has expanded beyond metabolic disease as researchers have begun exploring their broader biological effects
The idea is to reposition the muscle aponeurotic system and establish an equilibrium to the action of the nasolabial musculature
As a class of drugs, GLP-1s have been shown to result in weight loss.[2] Common side effects of GLP-1s include nausea, vomiting, diarrhea, constipation, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, and gastroenteritis.[1-4] All GLP-1s carry a boxed warning for the risk of thyroid c-cell tumors and a contraindication for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2